DNA/MVA prime-boost HIV vaccine

Current Opinion in Investigational Drugs

Volumn 8, Issue 2, 2007, Pages 159-167

  Kent, Stephen ^a   De Rose, Robert ^a   Rollman, Erik ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; DNA VACCINE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MODIFIED VACCINIA ANKARA 571; MODIFIED VACCINIA ANKARA HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN VACCINE; MODIFIED VACCINIA ANKARA RENTA VACCINE; MODIFIED VACCINIA ANKARA VACCINE; PLACEBO; PROTEIN P17; PTHRHUMAN IMMUNODEFICIENCY VIRUS ANTIGEN DNA VACCINE; PTHRRENTA DNA VACCINE; RENTA VACCINE; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS VACCINE; VIRUS VECTOR;

CLINICAL TRIAL; DNA VECTOR; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LABORATORY TEST; NONHUMAN; REVIEW; SIDE EFFECT; VACCINATION; VACCINIA VIRUS; ANIMAL; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; KENYA; PHASE 2 CLINICAL TRIAL; UNITED KINGDOM;

AIDS VACCINES; ANIMALS; CLINICAL TRIALS, PHASE II; GREAT BRITAIN; HIV INFECTIONS; HUMANS; KENYA; VACCINES, DNA; VACCINIA VIRUS;

EID: 33947324485     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. 231784 Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD J VIROL 1994 68 7 4650-4655
2. 245552 Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Hu SL, Abrams K, Barber GN, Moran P, Zarling JM, Langlois AJ, Kuller L, Morton WR, Benveniste RE SCIENCE 1992 255 5043 456-459
3. 315825 DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: Immunogenicity in mice. Hanke T, Schneider J, Gilbert SC, Hill AV, McMichael A VACCINE 1998 16 4 426-435
4. 333340 Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. Kent SJ, Zhao A, Best SJ, Chandler JD, Boyle DB, Ramshaw IA J VIROL 1998 72 12 10180-10188
5. 333344 Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, Hannan CM, Becker M, Sinden R, Smith GL, Hill AV NAT MED 1998 4 4 397-402
6. 374069 First AIDS vaccine designed for Africa is cleared for testing in humans. IAVI's Scientific Blueprint 2000 seeks head-to-head trials and compressed timelines; with 'goal in sight,' IAVI urges US $1.1 billion in new funding for focused R&D effort. The International AIDS Vaccine Initiative PRESS RELEASE 2000 July 11
7. 397054 Trials of first AIDS vaccine candidate designed for Africa to begin. International AIDS Vaccine Initiative PRESS RELEASE 2001 January 27
8. 397680 Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus ankara boost regimen. Allen TM, Vogel TU, Fuller DH, Mothe BR, Steffen S, Boyson JE, Shipley T, Fuller J, Hanke T, Sette A, Altman JD et al J IMMUNOL 2000 164 9 4968-4978
9. 436675 Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L et al NATURE 2002 415 6869 331-335
10. 450943 Oxxon Pharmaccines; products in development; key collaborations. Oxxon Pharmaccines Ltd COMPANY WORLD WIDE WEB SITE 2002 May 14
11. 510278 Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. Hanke T, Samuel RV, Blanchard TJ, Neumann VC, Allen TM, Boyson JE, Sharpe SA, Cook N, Smith GL, Watkins DI, Cranage MP, McMichael AJ J VIROL 1999 73 9 7524-7532
12. 510323 Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice. Hanke T, Blanchard TJ, Schneider J, Ogg GS, Tan R, Becker M, Gilbert SC, Hill AV, Smith GL, McMichael A J GEN VIROL 1998 79 1 83-90
13. 587512 2004 sanofi-aventis results: Research and development. sanofiaventis COMPANY PRESENTATION 2005 March 01.
14. 619857 Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, Bilska M, Craiu A, Zheng XX, Krivulka GR, Beaudry K et al SCIENCE 2000 290 486-492
15. 720648 Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. Goonetilleke N, Moore S, Dally L, Winstone N, Cebere I, Mahmoud A, Pinheiro S, Gillespie G, Brown D, Loach VRJ, Guimaraes-Walker A et al J VIROL 2006 80 10 4717-4728
16. 720649 Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine. Dorrell L, Yang H, Ondondo B, Dong T, di Gleria K, Suttill A, Conlon C, Brown D, Williams P, Bowness P, Goonetilleke N et al J VIROL 2006 80 10 4705-4716
17. 720650 Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Cebere I, Dorrell L, McShane H, Simmons A, McCormack S, Schmidt C, Smith C, Brooks M, Roberts JE, Darwin SC, Fast PE et al VACCINE 2006 24 4 417-425
18. 720654 Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ T cell responses. Estcourt MJ, Letourneau S, McMichael AJ, Hanke T EUR J IMMUNOL 2005 35 9 2532-2540
19. 720656 Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice. Hanke T, McMichael AJ, Dennis MJ, Sharpe SA, Powell LAJ, McLoughlin L, Crome SJ VACCINE 2005 23 12 1507-1514
20. 720658 Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa. Nkolola JP, Wee EGT, Im E-J, Jewell CP, Chen N, Xu X-N, McMichael AJ, Hanke T GENE THER 2004 11 13 1068-1080
21. 720659 A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: Stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. Mwau M, Cebere I, Sutton J, Chikoti P, Winstone N, Wee EGT, Beattie T, Chen YH, Dorrell L, McShane H, Schmidt C et al J GEN VIROL 2004 85 4 911-919
22. 720662 Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya. Hanke T, McMichael AJ, Samuel RV, Powell LAJ, McLoughlin L, Crome SJ, Edlin A VACCINE 2002 21 1-2 108-114
23. 720663 Development of a DNA-MVA/HIVA vaccine for Kenya. Hanke T, McMichael AJ, Mwau M, Wee EGT, Ceberej I, Patel S, Sutton J, Tomlinson M, Samuel RV VACCINE 2002 20 15 1995-1998
24. 720664 A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques. Wee EGT, Patel S, McMichael AJ, Hanke T J GEN VIROL 2002 83 1 75-80
25. 720674 Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Hanke T, McMichael AJ NAT MED 2000 6 9 951-955
26. 728357 High-dose recombinant canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. Goepfert PA, Horton H, McElrath MJ, Gurunathan S, Ferrari G, Tomaras GD, Montefiori DC, Allen M, Chiu YL, Spearman P, Fuchs JD et al INFECT DIS 192 7 1249-1259
27. mac239 infection. Allen TM, Jing P, Calore B, Horton H, O'Connor DH, Hanke T, Piekarczyk M, Ruddersdorf R, Mothe BR, Emerson C, Wilson N et al J VIROL 2002 76 20 10507-10511
28. 745506 Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, Montefiori DC, Xu Y, Herndon JG, Wyatt LS, Candido MA et al SCIENCE 2001 292 5514 69-74
29. 745508 Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Gu L, Martin JE, Novik L, Chakrabarti BK, Butman BT et al J INFECT DIS 2006 194 12 1638-1649
30. 745509 Efficacy of DNA and fowlpoxvirus prime/boost vaccines for simian/human immunodeficiency virus. Dale CJ, De Rose R, Stratov I, Chea S, Montefiori DC, Thomson S, Ramshaw IA, Coupar BE, Boyle DB, Law M, Kent SJ J VIROL 2004 78 24 13819-13828
31. 745669 A shot in the arm for AIDS vaccine research. Ho DD PLOS MED 2005 2 2 e36
32. 745754 Induction of long-lasting multi-specific CD8+ T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques. Im EJ, Nkolola JP, di Gleria K, McMichael AJ, Hanke T EUR J IMMUNOL 2006 36 10 2574-2584
33. 745760 A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. Kelleher AD, Puls RL, Bebbington M, Boyle D, French R, Kent SJ, Kippax S, Purcell DF, Thomson S, Wand H, Cooper DA et al AIDS 2006 20 2 294-297
34. 745800 The rationale behind a vaccine based on multiple HIV antigens. Rollman E, Brave A, Boberg A, Gudmundsdotter L, Engstrom G, Isaguliants M, Ljungberg K, Lundgren B, Blomberg P, Hinkula J, Hejdeman B et al MICROBES INFECT 2005 7 14 1414-1423
35. 746295 Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Shiver JW, Emini EA ANNU REV MED 2004 55 355-372
36. 746420 Multiprotein HIV type 1 clade B DNA/MVA vaccine: Construction, safety, and immunogenicity in macaques. Smith JM, Amara RR, McClure HM, Patel M, Sharma S, Yi H, Chennareddi L, Herndon JG, Butera ST, Heneine W, Ellenberger DL et al AIDS RES HUM RETROVIRUSES 2004 20 6 654-665
37. 746507 Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Martin JE, McCluskey MM, Chakrabarti BK, Lamoreaux L, Andrews CA et al J INFECT DIS 2006 194 12 1650-1660
38. 746509 Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Hanke T, Blanchard TJ, Schneider J, Hannan CM, Becker M, Gilbert SC, Hill AV, Smith GL, McMichael A VACCINE 1998 16 5 439-445
39. 746745 Dose-response relationship of DNA and recombinant fowlpoxvirus prime-boost vaccines: Implications for future trials. De Rose R, Sullivan MT, Dale CJ, Kelleher AD, Emery S, Cooper DA, Ramshaw IA, Boyle DB, Kent SJ HUM VACCIN 2006 2 3 134-136
40. 747372 AIDS: From crisis management to sustained strategic response. Piot P LANCET 2006 368 9534 526-530
41. 747374 Progress and obstacles in the development of an AIDS vaccine. Letvin NL NAT REV IMMUNOL 2006 6 12 930-939
42. 749956 Priming with a candidate HIV-1 clade A DNA vaccine followed by booster with HIV-1 clade A MVA vaccine in volunteers at low risk of HIV infection. Guimaraes-Walker A, Mackie N, McMichael A, Weber J, McCormack S, Cebere I, Kay R, Hanke T, Dally L, Gibianski L, Legg K et al AIDS VACCINE 2004 3 Abs 55
43. 750077 Generation of enhanced immune responses by consecutive immunisation with DNA and recombinant fowlpox viruses. Leong KH, Ramsay AJ, Morin MJ, Robinson HL, Boyle DB, Ramshaw IA. In: VACCINES 95, Brown F, Chanock H & Norrby E (Eds), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA 1995 327-331
44. 750170 Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus. Davenport MP, Ribeiro RM, Chao DL, Perelson AS J VIROL 2004 78 20 11340-11351
45. 750183 Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, Racz P, Tenner-Racz K, Dalesandro M, Scallon BJ, Ghrayeb J et al Science 1999 283 5403 857-860
46. 751958 Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Moss B, Carroll MW, Wyatt LS, Bennink JR, Hirsch VM, Goldstein S, Elkins WR, Fuerst TR, Lifson JD, Piatak M, Restifo NP ADV EXP MED BIOL 1996 397 7-13
47. 751961 Nonreplicating vaccinia vector efficiently expresses recombinant genes. Sutter G, Moss B PROC NATL ACAD SCI USA 1992 89 22 10847-10851
48. 753120 2004 Mid-year progress report. International AIDS Vaccine Initiative COMPANY PUBLICATION 2004 November 15 http://www.iavi.org/
49. 753139 Safety and immunogenicity of DNA and MVA HIVA vaccines in phase I HIV-1 vaccine trials in Nairobi, Kenya. Jaoko W, Omosa G, Bhatt K, Matu L, Ogutu H, Wakasiaka S, Odada J, Anzala O, Bashir F, Oyaro M, Indangasi J et al AIDS VACCINE 2004 3 Abs 56
50. 754700 Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. Hanke T, McMichael AJ, Dorrell L J GEN VIROL 2007 88 1 1-12
51. 754704 International AIDS Vaccine Initiative abandons lead vaccine candidate, citing poor responses. Meldrum J PRESS RELEASE 2004 September 01 http://www.aidsmap.com